Advanced search

Combine gene, variant, phenotype, region and year filters

Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.

Transparent by designEvery result links extracted entities to its source sentence and publication identifier.

Knowledge-base search

About your search

Phenotype

Lung cancer

398articles

398mentions

12co-reported genes shown

Most co-reported genes (articles)

Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.

5 records shown · first 60

PMID 41351921 | DOI 10.1016/j.ejmech.2025.118411 · European journal of medicinal chemistry · 2026 · 3 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
phenotype	lung cancer	“The epidermal growth factor receptor (EGFR) stands as a cornerstone therapeutic target in oncology, particularly non-small cell lung cancer (NSCLC), where it drives tumor proliferation amid a saturated field of inhibitors and analyses.”	0.98	phenotype_alias_lexicon_v2
variant	C797S	“Across more than 50 quinazoline-based and alternative scaffolds, we uncover universal binding drivers alongside tailored tweaks, including triazole add-ons that boost affinity for T790 M and C797S variants by two-fold to five-fold, curbing off-target effects.”	0.82	literature_variant_regex_v2
gene	EGFR	“The epidermal growth factor receptor (EGFR) stands as a cornerstone therapeutic target in oncology, particularly non-small cell lung cancer (NSCLC), where it drives tumor proliferation amid a saturated field of inhibitors and analyses.”	0.98	hgnc_dict_v1

PMID 41920754 | DOI 10.2174/0113895575451047260306044852 · Mini reviews in medicinal chemistry · 2026 · 3 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
phenotype	lung cancer	“UNLABELLED: Introduction / Objectives: Resistance to chemotherapies represents a critical challenge in the treatment of Non-Small Cell Lung Cancer (NSCLC).”	0.98	phenotype_alias_lexicon_v2
variant	C797S	“DISCUSSION: They target the mutant-EGFR to overcome the tertiary resistant mutations (Del19/T790M/C797S), which represent a major clinical challenge against other Tyrosine Kinase Inhibitors (TKIs).”	0.82	literature_variant_regex_v2
variant	T790M	“DISCUSSION: They target the mutant-EGFR to overcome the tertiary resistant mutations (Del19/T790M/C797S), which represent a major clinical challenge against other Tyrosine Kinase Inhibitors (TKIs).”	0.82	literature_variant_regex_v2

PMID 41987835 | PMCID PMC13077434 | DOI 10.3389/fchem.2026.1753911 · Frontiers in chemistry · 2026 · 3 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
phenotype	lung cancer	“BACKGROUND/OBJECTIVES: Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related death globally.”	0.98	phenotype_alias_lexicon_v2
variant	C797S	“Resistance to third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, particularly due to the C797S mutation, poses a significant clinical challenge.”	0.82	literature_variant_regex_v2
gene	EGFR	“A multi-stage computational pipeline for repurposing FDA-approved drugs: application to EGFR C797S-mutant NSCLC.”	0.98	hgnc_dict_v1

PMID 39756062 | DOI 10.1080/1061186X.2024.2449495 · Journal of drug targeting · 2025 · 4 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
phenotype	lung cancer	“Mutations that overexpress the epidermal growth factor receptor (EGFR) are linked to cancers like breast (15-20%), head and neck (10-15%), colorectal (5-8%), and non-small cell lung cancer (10-50%), especially in East Asian populations.”	0.98	phenotype_alias_lexicon_v2
variant	C797S	“Secondary mutations (e.g. 'T790M', 'C797S'), off-target effects, and resistance due to alternate pathway activation reduce the efficacy of currently available EGFR inhibitors.”	0.82	literature_variant_regex_v2
gene	EGFR	“Epidermal growth factor receptors unveiled: a comprehensive survey on mutations, clinical insights of global inhibitors, and emergence of heterocyclic derivatives as EGFR inhibitors.”	0.98	hgnc_dict_v1
variant	T790M	“Secondary mutations (e.g. 'T790M', 'C797S'), off-target effects, and resistance due to alternate pathway activation reduce the efficacy of currently available EGFR inhibitors.”	0.82	literature_variant_regex_v2

PMID 32739648 | DOI 10.1016/j.ejmech.2020.112640 · European journal of medicinal chemistry · 2020 · 4 validated mentions

Evidence preview

Type	Entity	Source evidence	Confidence	Extractor
phenotype	lung cancer	“The over expression of EGFR has been recognized as the driver mechanism in the occurrence and progression of carcinomas such as lung cancer, breast cancer, pancreatic cancer, etcetera.”	0.98	phenotype_alias_lexicon_v2
variant	C797S	“Newer mutations like C797S cause failure of Osimertinib and other EGFR TKIs belonging to the third-generation caused by the development of resistance.”	0.82	literature_variant_regex_v2
gene	EGFR	“Novel quinazoline-based EGFR kinase inhibitors: A review focussing on SAR and molecular docking studies (2015-2019).”	0.98	hgnc_dict_v1
phenotype	breast cancer	“The over expression of EGFR has been recognized as the driver mechanism in the occurrence and progression of carcinomas such as lung cancer, breast cancer, pancreatic cancer, etcetera.”	0.98	phenotype_alias_lexicon_v2